Download - Tharanga lecture
![Page 1: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/1.jpg)
1
Anticoagulant, Antiplatelet, and Thrombolytic Drugs
Dr. Tharanga Kulathilaka
![Page 2: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/2.jpg)
2
Objectives
• Normal haemostasis process Plt plug, Clot & Thrombus
• Mechanism of action
• Indications
• Common side effects
![Page 3: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/3.jpg)
3
Haemostasis
• Complex process• Interaction between vessel wall, plt, Coagualtion/
fibrinolytic mechanism.
• Vessel wall in normal condition prevents plt adhesion and thrombin formation by negative charge, PC, NO synthesis, Production of plasminogen activator, Expression of thrombomodulin and heparan sulphate.
![Page 4: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/4.jpg)
4
Physiology and Pathophysiology of Coagulation
• Hemostasis– Stage 1—formation of platelet plug
• Platelet aggregation– Stage 2—coagulation
• Intrinsic coagulation pathway• Extrinsic coagulation pathway
– Keeping hemostasis under control– Physiologic removal of clots
• Thrombosis– Arterial thrombosis, Venous thrombosis
![Page 5: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/5.jpg)
5
![Page 6: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/6.jpg)
6
• Endothelial injury is caused by Mechanical stresses (HT)
Biochemical abnormalities ( Modified LDL, DM, Plasma homocystein )
Immunological factors
Free radicals
Inflammation
Genetic alteration
![Page 7: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/7.jpg)
7
Platelets
![Page 8: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/8.jpg)
8
Platelet plug formation
![Page 9: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/9.jpg)
9
Clotting pathway
![Page 10: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/10.jpg)
10
Thrombus
![Page 11: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/11.jpg)
11
Physiological limitations of coagulation
• Rapid blood flow
• Circulating inhibitors of clotting factors
• Antithrombin – Heparin
• Act protein c (-)V ,viii
• Protein S cofactor for protein C
![Page 12: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/12.jpg)
12
Fibrinolysis
• Fibrinolysis is the controlled remodeling of a platelet plug. It is the process that dissolves fibrin resulting in the removal of small blot clots. Agents or drugs which promote fibrinolysis are useful therapeutically.
• Plasminogen – Plasmin
• Tpa
• FDP - D dimers
![Page 13: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/13.jpg)
13
Overview of DrugsDrug Class Prototype Drug Action
Therapeutic Effect
Anticoagulants: Parenteral
Heparin Fibrin formation (by promoting inactivation of clotting factors)
Prevention of venous thrombosis
Anticoagulants: Oral
Warfarin Fibrin formation (by decreasing synthesis of clotting factors)
Prevention of venous thrombosis
Antiplatelet Drugs
Aspirin Platelet aggregations
Prevention of arterial thrombosis
Thrombolytic Drugs
Streptokinase Promotion of fibrin digestion
Removal of newly formed thrombi
![Page 14: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/14.jpg)
14
Antiplatelet Drugs
Two Drugs to know:
ASPIRIN and CLOPIDOGREL
![Page 15: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/15.jpg)
15
Antiplatelet Drugs
• Aspirin (ASA)– Irreversible Inhibition of cyclooxygenase
reducing Txa2
Effect lasts for 7 days.– Adverse effects
• Increase risk of GI bleeding• Hypersensitivity• Bronchospasms• Interstitial nephritis and protenuria• Rayes syndrome
• Clopidogrel [Plavix]– Orally active– ADP receptor antagonist– Prevents/reduces thrombotic events (MI, ischemic stroke, vascular
death)
![Page 16: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/16.jpg)
16
Cont Anti plt drugs
• Clopidogrel – ADP receptor blocker in plt membrane
• Prevents ADP dependent activation of gpǁb, ǁl a complex
• Prasugrel - Potent and rapid action
• Dipiridamole – Inhibits plt phosphodiesterase activity increses pgi2 action
![Page 17: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/17.jpg)
17
Plt llb,llla blockers
• Abciximab
• Eptifibatide
• Tirofiban
• Excessive bleeding
• Its uses yet to indentify
• During pci
![Page 18: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/18.jpg)
18
Parenteral Anticoagulants I:Heparin and Related Drugs
Heparin (Unfractionated Heparin)• Sources
– Lungs of cattle– Intestines of pigs
• Rapid-acting anticoagulant• Uses
– Pulmonary embolism (PE)– Stroke evolving– Massive deep venous thrombosis (DVT)
![Page 19: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/19.jpg)
19
Parenteral Anticoagulants I:Heparin and Related Drugs
• Adverse effects
– Hemorrhage
– Heparin-induced thrombocytopenia
– Hypersensitivity reactions
• Protamine
• Activated partial thromboplastin time (aPTT)
![Page 20: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/20.jpg)
20
Figure 51-3 Mechanism of action of heparin, LMW heparins, and fondaparinux.
Heparin suppresses coagulation by promoting the action of antithrombin (a serine protease inhbitor) to inactivate thrombin and factor Xa.
![Page 21: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/21.jpg)
21
Low-Molecular-Weight HeparinsLovenox (enoxaparin)
• Heparin preparations composed of molecules that are shorter than those found in unfractionated heparin. – Lovenox (enoxaparin)
• Therapeutic use– Prevention of DVT following surgery– Treatment of established DVT– Prevention of ischemic complications
• Adverse effects and interactions– Bleeding, immune-mediated thrombocytopenia– Cost
![Page 22: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/22.jpg)
22
Fondaparinux [Arixtra]
• Synthetic subQ anticoagulant – like LMW heparin• Selective inhibition of Factor Xa – see Figure 51-3• Therapeutic use
– Prevention of DVT following surgery– Treatment of acute PE (with warfarin)– Treatment of acute DVT (with warfarin)
• Adverse effects– Bleeding is the biggest concern, risk is increased
with advancing age and renal impairment– Patients weighting less than 50 kg. low BW
increases bleeding risk
![Page 23: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/23.jpg)
23
Parenteral Anticoagulants II:Direct Thrombin Inhibitors
Bivalirudin [Angiomax]• Therapeutic use
– Prevent clot formation (combined with aspirin)• Mechanism of action
– Direct, reversible inhibitor of thrombin– Prevents the conversion of fibrinogen into fibrin– Prevents factor XIIIa activation
• Adverse effects– Back pain, headache
![Page 24: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/24.jpg)
24
Parenteral Anticoagulants II:Direct Thrombin Inhibitors
Bivalirudin [Angiomax]• synthetic peptide,
must be injected IV• short half-life (25
min)• very expensive
![Page 25: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/25.jpg)
25
Warfarin• Oral anticoagulant• Antagonist of vitamin K-dependent reactions• Blocks the biosynthesis of four clotting factors:
Factors VII, IX, X, and prothrombin• Reduces production of clotting factors by 30-50%• Therapeutic uses
Long-term prophylaxis of thrombosis• Prevention of venous thrombosis and associated
pulmonary embolism• Prevention of thromboembolism (in patients with
prosthetic heart valves)• Prevention of thrombosis during atrial fibrillation
![Page 26: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/26.jpg)
26
Warfarin
• Adverse effects
– Hemorrhage
– Fetal hemorrhage and teratogenesis from use during pregnancy
– Use during lactation – warfarin enters breast milk
![Page 27: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/27.jpg)
27
Warfarin
• Drug interactions
– Drugs that increase anticoagulant effects
– Drugs that promote bleeding
– Drugs that decrease anticoagulant effects
– Heparin
– Aspirin
– Acetaminophen
![Page 28: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/28.jpg)
28
Thrombolytic Drugs – Clot Busters
• Streptokinase [Streptase]
– Binds plasminogen and facilitates plasmin formation – plasmin digests fibrin of clots
– Most effective when therapy is begun within 6 hours of symptom onset
– Intended for IV or intracoronary administration
• Uses
– Acute coronary thrombosis (acute MI)
– Deep venous thrombosis (DVT)
– Massive pulmonary emboli
• Adverse effects
– Bleeding, hypotension
![Page 29: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/29.jpg)
29
tPA
• Alteplase
• Reteplase
• More specific for clot bound plasminogen
• Fewer bleeding episodes
• Expensive
![Page 30: Tharanga lecture](https://reader036.vdocument.in/reader036/viewer/2022062704/55632804d8b42ad7398b4c85/html5/thumbnails/30.jpg)
30
THANK YOU